Citius Oncology Gets Nasdaq Extension to April 19, 2027, to Meet Minimum Bid Price Rule

By Public Technologies
  • Citius Oncology received Nasdaq's extension notice October 19, 2026, setting April 19, 2027, as its $1 minimum bid-price compliance deadline.
  • Compliance requires the common stock's closing bid price to reach at least $1 for a minimum of 10 consecutive business days.
  • Failure to regain compliance by the deadline would trigger a delisting notice; the company may appeal to a Nasdaq hearings panel.
  • The extension leaves the common stock trading on the Nasdaq Capital Market under CTOR while the company evaluates compliance options.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-112109), on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.